$VTAE, Can Vitae Pharmaceuticals, Inc. (NASDA
Post# of 22755
Posted On: 03/14/2016 4:36:08 PM
$VTAE,
Can Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Top Street’s Expectations?
By Stocks Daily Staff -
March 14, 2016
SHARE
Facebook
Twitter
The research entity Zacks drafted a research report on Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) and as per it’s the company’s stock can touch $23 in FY2017. Zacks polled 2 brokerage houses and after that determined price target of $21.5 on the stock. As per the latest update, the bearish price forecast stands at $20.
Zacks Research has assigned 1.5 rating to Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE). Investors at all times look to pour in their funds in the stocks termed best in the industry. Market participants who realize the worth of research initiate their investment journey by following the Industry Rank given by prominent firms. Additionally, the stockholders can look to refer mean rating on the stock before investing in the stock
It is an acknowledged fact that the brokerage houses use individual rating mechanism to draft research reports. This is very much required as the stock gets buy rating from some firms, sell from other group and likewise. However, Zacks has designed a unique mechanism wherein it considers the stock views of renowned analysts, calculates mean and then only assigns a rating on a ‘1-5′ scale. This Zacks rating is popularly termed as the ‘Average Brokerage Recommendation’.
It is worth mentioning that there are several factors considered by analysts for performing stock revision and get a stock score. In the list of key factors, the parameter that scores the topmost place is firm’s fiscal report. For the most part directs shareholders to gauge the price movement of stock. For the quarter closed on 2015-12-31, Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) posted EPS of $-0.57. The earnings were $0.1 below than the Zacks released estimates, highlighting an unanticipated divergence of 16.13%.
For the approaching quarter, the Wall Street is forecasting N/A to register EPS of $-0.57, representing the views of 2 brokerages.
Discover Which Stocks Can Turn Every $10,000 into $42,749!
It's a new way to trade stocks with a 91% to 100% success rate, and earn between 8% and 199% in as little as 14 days. This strategy has nothing to do with using options to short the market. In fact, you buy stocks the same way you do now… but with one simple difference.
Click Here To See How It Works.
Can Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Top Street’s Expectations?
By Stocks Daily Staff -
March 14, 2016
SHARE
The research entity Zacks drafted a research report on Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) and as per it’s the company’s stock can touch $23 in FY2017. Zacks polled 2 brokerage houses and after that determined price target of $21.5 on the stock. As per the latest update, the bearish price forecast stands at $20.
Zacks Research has assigned 1.5 rating to Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE). Investors at all times look to pour in their funds in the stocks termed best in the industry. Market participants who realize the worth of research initiate their investment journey by following the Industry Rank given by prominent firms. Additionally, the stockholders can look to refer mean rating on the stock before investing in the stock
It is an acknowledged fact that the brokerage houses use individual rating mechanism to draft research reports. This is very much required as the stock gets buy rating from some firms, sell from other group and likewise. However, Zacks has designed a unique mechanism wherein it considers the stock views of renowned analysts, calculates mean and then only assigns a rating on a ‘1-5′ scale. This Zacks rating is popularly termed as the ‘Average Brokerage Recommendation’.
It is worth mentioning that there are several factors considered by analysts for performing stock revision and get a stock score. In the list of key factors, the parameter that scores the topmost place is firm’s fiscal report. For the most part directs shareholders to gauge the price movement of stock. For the quarter closed on 2015-12-31, Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) posted EPS of $-0.57. The earnings were $0.1 below than the Zacks released estimates, highlighting an unanticipated divergence of 16.13%.
For the approaching quarter, the Wall Street is forecasting N/A to register EPS of $-0.57, representing the views of 2 brokerages.
Discover Which Stocks Can Turn Every $10,000 into $42,749!
It's a new way to trade stocks with a 91% to 100% success rate, and earn between 8% and 199% in as little as 14 days. This strategy has nothing to do with using options to short the market. In fact, you buy stocks the same way you do now… but with one simple difference.
Click Here To See How It Works.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼